Contact, publication, and social network information about Harvard faculty and fellows. Harvard Catalyst Profiles
Keywords
Last Name
Institution

Susan Ellen Waisbren, Ph.D.

TitleAssociate Professor of Psychology in the Department of Psychiatry
InstitutionChildren's Hospital Boston
DepartmentPsychiatry
AddressChildren's Hospital
Room 525
One Autumn Street
Boston MA 02215
Phone617/355-4686
Fax617/730-0907

 Bibliographic 
 selected publications
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
List All   |   Timeline
  1. Waisbren SE, Landau Y, Wilson J, Vockley J. Neuropsychological outcomes in fatty acid oxidation disorders: 85 cases detected by newborn screening. Dev Disabil Res Rev. 2013 Jun; 17(3):260-8.
    View in: PubMed
  2. Jumbo-Lucioni PP, Garber K, Kiel J, Baric I, Berry GT, Bosch A, Burlina A, Chiesa A, Pico ML, Estrada SC, Henderson H, Leslie N, Longo N, Morris AA, Ramirez-Farias C, Schweitzer-Krantz S, Silao CL, Vela-Amieva M, Waisbren S, Fridovich-Keil JL. Erratum to: Diversity of approaches to classic galactosemia around the world: a comparison of diagnosis, intervention, and outcomes. J Inherit Metab Dis. 2012 Nov; 35(6):1157.
    View in: PubMed
  3. Jumbo-Lucioni PP, Garber K, Kiel J, Baric I, Berry GT, Bosch A, Burlina A, Chiesa A, Pico ML, Estrada SC, Henderson H, Leslie N, Longo N, Morris AA, Ramirez-Farias C, Scheweitzer-Krantz S, Silao CL, Vela-Amieva M, Waisbren S, Fridovich-Keil JL. Diversity of approaches to classic galactosemia around the world: a comparison of diagnosis, intervention, and outcomes. J Inherit Metab Dis. 2012 Nov; 35(6):1037-49.
    View in: PubMed
  4. Craig WY, Allan WC, Kloza EM, Pulkkinen AJ, Waisbren S, Spratt DI, Palomaki GE, Neveux LM, Haddow JE. Mid-gestational maternal free thyroxine concentration and offspring neurocognitive development at age two years. J Clin Endocrinol Metab. 2012 Jan; 97(1):E22-8.
    View in: PubMed
  5. Bird LM, Tan WH, Bacino CA, Peters SU, Skinner SA, Anselm I, Barbieri-Welge R, Bauer-Carlin A, Gentile JK, Glaze DG, Horowitz LT, Mohan KN, Nespeca MP, Sahoo T, Sarco D, Waisbren SE, Beaudet AL. A therapeutic trial of pro-methylation dietary supplements in Angelman syndrome. Am J Med Genet A. 2011 Dec; 155A(12):2956-63.
    View in: PubMed
  6. Waisbren SE, Potter NL, Gordon CM, Green RC, Greenstein P, Gubbels CS, Rubio-Gozalbo E, Schomer D, Welt C, Anastasoaie V, D'Anna K, Gentile J, Guo CY, Hecht L, Jackson R, Jansma BM, Li Y, Lip V, Miller DT, Murray M, Power L, Quinn N, Rohr F, Shen Y, Skinder-Meredith A, Timmers I, Tunick R, Wessel A, Wu BL, Levy H, Elsas L, Berry GT. The adult galactosemic phenotype. J Inherit Metab Dis. 2012 Mar; 35(2):279-86.
    View in: PubMed
  7. Gubbels CS, Maurice-Stam H, Berry GT, Bosch AM, Waisbren S, Rubio-Gozalbo ME, Grootenhuis MA. Psychosocial developmental milestones in men with classic galactosemia. J Inherit Metab Dis. 2011 Apr; 34(2):415-9.
    View in: PubMed
  8. Tan WH, Bacino CA, Skinner SA, Anselm I, Barbieri-Welge R, Bauer-Carlin A, Beaudet AL, Bichell TJ, Gentile JK, Glaze DG, Horowitz LT, Kothare SV, Lee HS, Nespeca MP, Peters SU, Sahoo T, Sarco D, Waisbren SE, Bird LM. Angelman syndrome: Mutations influence features in early childhood. Am J Med Genet A. 2011 Jan; 155A(1):81-90.
    View in: PubMed
  9. Gentile JK, Tan WH, Horowitz LT, Bacino CA, Skinner SA, Barbieri-Welge R, Bauer-Carlin A, Beaudet AL, Bichell TJ, Lee HS, Sahoo T, Waisbren SE, Bird LM, Peters SU. A neurodevelopmental survey of Angelman syndrome with genotype-phenotype correlations. J Dev Behav Pediatr. 2010 Sep; 31(7):592-601.
    View in: PubMed
  10. Peters SU, Bird LM, Kimonis V, Glaze DG, Shinawi LM, Bichell TJ, Barbieri-Welge R, Nespeca M, Anselm I, Waisbren S, Sanborn E, Sun Q, O'Brien WE, Beaudet AL, Bacino CA. Double-blind therapeutic trial in Angelman syndrome using betaine and folic acid. Am J Med Genet A. 2010 Aug; 152A(8):1994-2001.
    View in: PubMed
  11. Yusupov R, Finegold DN, Naylor EW, Sahai I, Waisbren S, Levy HL. Sudden death in medium chain acyl-coenzyme a dehydrogenase deficiency (MCADD) despite newborn screening. Mol Genet Metab. 2010 Sep; 101(1):33-9.
    View in: PubMed
  12. Seminara J, Tuchman M, Krivitzky L, Krischer J, Lee HS, Lemons C, Baumgartner M, Cederbaum S, Diaz GA, Feigenbaum A, Gallagher RC, Harding CO, Kerr DS, Lanpher B, Lee B, Lichter-Konecki U, McCandless SE, Merritt JL, Oster-Granite ML, Seashore MR, Stricker T, Summar M, Waisbren S, Yudkoff M, Batshaw ML. Establishing a consortium for the study of rare diseases: The Urea Cycle Disorders Consortium. Mol Genet Metab. 2010; 100 Suppl 1:S97-105.
    View in: PubMed
  13. Brumm VL, Bilder D, Waisbren SE. Psychiatric symptoms and disorders in phenylketonuria. Mol Genet Metab. 2010; 99 Suppl 1:S59-63.
    View in: PubMed
  14. Koch R, Trefz F, Waisbren S. Psychosocial issues and outcomes in maternal PKU. Mol Genet Metab. 2010; 99 Suppl 1:S68-74.
    View in: PubMed
  15. White DA, Waisbren S, van Spronsen FJ. Final commentary: a new chapter. Mol Genet Metab. 2010; 99 Suppl 1:S106-7.
    View in: PubMed
  16. White DA, Waisbren S, van Spronsen FJ. The psychology and neuropathology of phenylketonuria. Mol Genet Metab. 2010; 99 Suppl 1:S1-2.
    View in: PubMed
  17. Waisbren S, White DA. Screening for cognitive and social-emotional problems in individuals with PKU: tools for use in the metabolic clinic. Mol Genet Metab. 2010; 99 Suppl 1:S96-9.
    View in: PubMed
  18. Lipstein EA, Perrin JM, Waisbren SE, Prosser LA. Impact of false-positive newborn metabolic screening results on early health care utilization. Genet Med. 2009 Oct; 11(10):716-21.
    View in: PubMed
  19. Lalani SR, Thakuria JV, Cox GF, Wang X, Bi W, Bray MS, Shaw C, Cheung SW, Chinault AC, Boggs BA, Ou Z, Brundage EK, Lupski JR, Gentile J, Waisbren S, Pursley A, Ma L, Khajavi M, Zapata G, Friedman R, Kim JJ, Towbin JA, Stankiewicz P, Schnittger S, Hansmann I, Ai T, Sood S, Wehrens XH, Martin JF, Belmont JW, Potocki L. 20p12.3 microdeletion predisposes to Wolff-Parkinson-White syndrome with variable neurocognitive deficits. J Med Genet. 2009 Mar; 46(3):168-75.
    View in: PubMed
  20. Prosser LA, Ladapo JA, Rusinak D, Waisbren SE. Parental Tolerance for False-Positive Newborn Screening Results. Arch Ped Adol Med. 2008; 162(9):870-6.
  21. Prosser LA, Ladapo JA, Rusinak D, Waisbren SE. Parental tolerance of false-positive newborn screening results. Arch Pediatr Adolesc Med. 2008 Sep; 162(9):870-6.
    View in: PubMed
  22. Anastasoaie V, Kurzius L, Forbes P, Waisbren S. Stability of blood phenylalanine levels and IQ in children with phenylketonuria. Mol Genet Metab. 2008 Sep-Oct; 95(1-2):17-20.
    View in: PubMed
  23. Waisbren SE, Levy HL, Noble M, Matern D, Gregersen N, Pasley K, Marsden D. Short-chain acyl-CoA dehydrogenase (SCAD) deficiency: an examination of the medical and neurodevelopmental characteristics of 14 cases identified through newborn screening or clinical symptoms. Mol Genet Metab. 2008 Sep-Oct; 95(1-2):39-45.
    View in: PubMed
  24. Waisbren SE. Expanded newborn screening: information and resources for the family physician. Am Fam Physician. 2008 Apr 1; 77(7):987-94.
    View in: PubMed
  25. Waisbren SE, Bowles H, Hasan T, Zou KH, Emans SJ, Goldberg C, Gould S, Levine D, Lieberman E, Loeken M, Longtine J, Nadelson C, Patenaude AF, Quinn D, Randolph AG, Solet JM, Ullrich N, Walensky R, Weitzman P, Christou H. Gender differences in research grant applications and funding outcomes for medical school faculty. J Womens Health (Larchmt). 2008 Mar; 17(2):207-14.
    View in: PubMed
  26. Young HK, Barton BA, Waisbren S, Portales Dale L, Ryan MM, Webster RI, North KN. Cognitive and psychological profile of males with Becker muscular dystrophy. J Child Neurol. 2008 Feb; 23(2):155-62.
    View in: PubMed
  27. Waisbren SE, Noel K, Fahrbach K, Cella C, Frame D, Dorenbaum A, Levy H. Phenylalanine blood levels and clinical outcomes in phenylketonuria: a systematic literature review and meta-analysis. Mol Genet Metab. 2007 Sep-Oct; 92(1-2):63-70.
    View in: PubMed
  28. Sahoo T, Bacino CA, German JR, Shaw CA, Bird LM, Kimonis V, Anselm I, Waisbren S, Beaudet AL, Peters SU. Identification of novel deletions of 15q11q13 in Angelman syndrome by array-CGH: molecular characterization and genotype-phenotype correlations. Eur J Hum Genet. 2007 Sep; 15(9):943-9.
    View in: PubMed
  29. Waisbren SE, Noel K, Fahrback K, Cella C, Frame D, Dorembaum A, Levy H. Phenylalanine blood levels and clinical outcomes in phenylketonuria: A systematic literature review and meta-analysis. Molec Genet Metab. 2007; 92(1-2):63-70.
  30. Waisbren SE. Newborn screening for metabolic disorders. JAMA. 2006 Aug 23; 296(8):993-5.
    View in: PubMed
  31. Hewlett J, Waisbren SE. A review of the psychosocial effects of false-positive results on parents and current communication practices in newborn screening. J Inherit Metab Dis. 2006 Oct; 29(5):677-82.
    View in: PubMed
  32. Veloudaki A, Waisbren SE, Bailey I, Rohr F. PKU Tool Kit for Transition to Adult Healthcare. 2006.
  33. Gurian EA, Kinnamon DD, Henry JJ, Waisbren SE. Expanded newborn screening for biochemical disorders: the effect of a false-positive result. Pediatrics. 2006 Jun; 117(6):1915-21.
    View in: PubMed
  34. Hewlett JM, Waisbren SE. Follow-up to Newborn Screening: A Guide for Parents. 2006.
  35. Hewlett JM, Waisbren SE. Newborn Screening Follow-up Question and Answer Fact Sheet. 2006.
  36. Gennaccaro M, Waisbren SE, Marsden D. The knowledge gap in expanded newborn screening: survey results from paediatricians in Massachusetts. J Inherit Metab Dis. 2005; 28(6):819-24.
    View in: PubMed
  37. Antshel KM, Epstein IO, Waisbren SE. Cognitive strengths and weaknesses in children and adolescents homozygous for the galactosemia Q188R mutation: a descriptive study. Neuropsychology. 2004 Oct; 18(4):658-64.
    View in: PubMed
  38. Waisbren SE, Rones M, Read CY, Marsden D, Levy HL. Brief report: Predictors of parenting stress among parents of children with biochemical genetic disorders. J Pediatr Psychol. 2004 Oct; 29(7):565-70.
    View in: PubMed
  39. Antshel KM, Brewster S, Waisbren SE. Child and parent attributions in chronic pediatric conditions: phenylketonuria (PKU) as an exemplar. J Child Psychol Psychiatry. 2004 Mar; 45(3):622-30.
    View in: PubMed
  40. Waisbren SE, Levy HL. Expanded screening of newborns for genetic disorders. JAMA. 2004 Feb 18; 291(7):820-1; author reply 821.
    View in: PubMed
  41. Waisbren SE, Albers S, Amato S, Ampola M, Brewster TG, Demmer L, Eaton RB, Greenstein R, Korson M, Larson C, Marsden D, Msall M, Naylor EW, Pueschel S, Seashore M, Shih VE, Levy HL. Effect of expanded newborn screening for biochemical genetic disorders on child outcomes and parental stress. Obstet Gynecol Surv. 2004; 59(6):415-417.
  42. Hanley WB, Azen C, Koch R, Michals-Matalon K, Matalon R, Rouse B, Trefz F, Waisbren S, de la Cruz F. Maternal Phenylketonuria Collaborative Study (MPKUCS)--the 'outliers'. J Inherit Metab Dis. 2004; 27(6):711-23.
    View in: PubMed
  43. Rohr F, Munier A, Sullivan D, Bailey I, Gennaccaro M, Levy H, Brereton H, Gleason S, Goss B, Lesperance E, Moseley K, Singh R, Tonyes L, Vespa H, Waisbren S. The Resource Mothers Study of Maternal Phenylketonuria: preliminary findings. J Inherit Metab Dis. 2004; 27(2):145-55.
    View in: PubMed
  44. Levy HL, Yu JJ, Waisbren SE. Maternal histidinaemia: pregnancies and offspring outcomes. J Inherit Metab Dis. 2004; 27(2):197-204.
    View in: PubMed
  45. Koch R, Hanley W, Levy H, Matalon K, Matalon R, Rouse B, Trefz F, Güttler F, Azen C, Platt L, Waisbren S, Widaman K, Ning J, Friedman EG, de la Cruz F. The Maternal Phenylketonuria International Study: 1984-2002. Pediatrics. 2003 Dec; 112(6 Pt 2):1523-9.
    View in: PubMed
  46. Waisbren SE, Azen C. Cognitive and behavioral development in maternal phenylketonuria offspring. Pediatrics. 2003 Dec; 112(6 Pt 2):1544-7.
    View in: PubMed
  47. Levy HL, Waisbren SE, Güttler F, Hanley WB, Matalon R, Rouse B, Trefz FK, de la Cruz F, Azen CG, Koch R. Pregnancy experiences in the woman with mild hyperphenylalaninemia. Pediatrics. 2003 Dec; 112(6 Pt 2):1548-52.
    View in: PubMed
  48. Antshel KM, Waisbren SE. Developmental timing of exposure to elevated levels of phenylalanine is associated with ADHD symptom expression. J Abnorm Child Psychol. 2003 Dec; 31(6):565-74.
    View in: PubMed
  49. Waisbren SE, Albers S, Amato S, Ampola M, Brewster TG, Demmer L, Eaton RB, Greenstein R, Korson M, Larson C, Marsden D, Msall M, Naylor EW, Pueschel S, Seashore M, Shih VE, Levy HL. Effect of expanded newborn screening for biochemical genetic disorders on child outcomes and parental stress. JAMA. 2003 Nov 19; 290(19):2564-72.
    View in: PubMed
  50. Antshel KM, Waisbren SE. Timing is everything: executive functions in children exposed to elevated levels of phenylalanine. Neuropsychology. 2003 Jul; 17(3):458-68.
    View in: PubMed
  51. Mitchell ML, Klein RZ, Sargent JD, Meter RA, Haddow JE, Waisbren SE, Faix JD. Iodine sufficiency and measurements of thyroid function in maternal hypothyroidism. Clin Endocrinol (Oxf). 2003 May; 58(5):612-6.
    View in: PubMed
  52. Waisbren SE, Read CY, Ampola M, Brewster TG, Demmer L, Greenstein R, Ingham CL, Korson M, Msall M, Pueschel S, Seashore M, Shih VE, Levy HL. Newborn screening compared to clinical identification of biochemical genetic disorders. J Inherit Metab Dis. 2002 Nov; 25(7):599-600.
    View in: PubMed
  53. Antshel KM, Gurian EA, Waisbren SE. Maternal phenylketonuria: a case study suggesting the use of prenatal psychotherapy to help control phenylalanine levels. Am J Orthopsychiatry. 2002 Oct; 72(4):577-84.
    View in: PubMed
  54. Levy HL, Vargas JE, Waisbren SE, Kurczynski TW, Roeder ER, Schwartz RS, Rosengren S, Prasad C, Greenberg CR, Gilfix BM, MacGregor D, Shih VE, Bao L, Kraus JP. Reproductive fitness in maternal homocystinuria due to cystathionine beta-synthase deficiency. J Inherit Metab Dis. 2002 Aug; 25(4):299-314.
    View in: PubMed
  55. Brown AS, Fernhoff PM, Waisbren SE, Frazier DM, Singh R, Rohr F, Morris JM, Kenneson A, MacDonald P, Gwinn M, Honein M, Rasmussen SA. Barriers to successful dietary control among pregnant women with phenylketonuria. Genet Med. 2002 Mar-Apr; 4(2):84-9.
    View in: PubMed
  56. Fowler DJ, Picker J, Waisbren SE, Levy HL. Neonatal screening for medium--chain acyl-CoA dehydrogenase deficiency. Lancet. 2002 Feb 16; 359(9306):628.
    View in: PubMed
  57. www.childrenshospital.org/newenglandconsortium. 2002.
  58. Finkelson L, Bailey I, Waisbren SE. PKU adults and their return to diet: predicting diet continuation and maintenance. J Inherit Metab Dis. 2001 Aug; 24(4):515-6.
    View in: PubMed
  59. Albers S, Waisbren SE, Ampola MG, Brewster TG, Burke LW, Demmer LA, Filiano J, Greenstein RM, Ingham CL, Korson MS, Marsden D, Schwartz RC, Seashore MR, Shih VE, Levy HL. New England Consortium: a model for medical evaluation of expanded newborn screening with tandem mass spectrometry. J Inherit Metab Dis. 2001 Apr; 24(2):303-4.
    View in: PubMed
  60. Waisbren SE, Albers S, Marsden D, Bailey I, Finkelson L, Lobbregt D, Korson M, Levy H and the New England Consortium of Metabolic Programs. Expanded newborn screening for metabolic diosrders: a giant leap forward in preventive medicine or Pandora's box?. J Law, Med Ethics. 2001; 29(2 Suppl (11)).
  61. Klein RZ, Sargent JD, Larsen PR, Waisbren SE, Haddow JE, Mitchell ML. Relation of severity of maternal hypothyroidism to cognitive development of offspring. J Med Screen. 2001; 8(1):18-20.
    View in: PubMed
  62. PKU Primer for Community Health Care Providers Treating Adolescents and Adults with PKU. 2001.
  63. Waisbren SE. Comments on cognition and intelligence in phenylketonuria. Eur J Pediatr. 2000 Oct; 159 Suppl 2:S80-1.
    View in: PubMed
  64. Koch R, Friedman E, Azen C, Hanley W, Levy H, Matalon R, Rouse B, Trefz F, Waisbren S, Michals-Matalon K, Acosta P, Güttler F, Ullrich K, Platt L, de la Cruz F. The International Collaborative Study of Maternal Phenylketonuria: status report 1998. Eur J Pediatr. 2000 Oct; 159 Suppl 2:S156-60.
    View in: PubMed
  65. Varvogli L, Repetto GM, Waisbren SE, Levy HL. High cognitive outcome in an adolescent with mut- methylmalonic acidemia. Am J Med Genet. 2000 Apr 3; 96(2):192-5.
    View in: PubMed
  66. Waisbren SE, Hanley W, Levy HL, Shifrin H, Allred E, Azen C, Chang PN, Cipcic-Schmidt S, de la Cruz F, Hall R, Matalon R, Nanson J, Rouse B, Trefz F, Koch R. Outcome at age 4 years in offspring of women with maternal phenylketonuria: the Maternal PKU Collaborative Study. JAMA. 2000 Feb 9; 283(6):756-62.
    View in: PubMed
  67. Vargas JE, Mudd SH, Waisbren SE, Levy HL. Maternal gamma-cystathionase deficiency: absence of both teratogenic effects and pregnancy complications. Am J Obstet Gynecol. 1999 Sep; 181(3):753-5.
    View in: PubMed
  68. Haddow JE, Palomaki GE, Allan WC, Williams JR, Knight GJ, Gagnon J, O'Heir CE, Mitchell ML, Hermos RJ, Waisbren SE, Faix JD, Klein RZ. Maternal thyroid deficiency during pregnancy and subsequent neuropsychological development of the child. N Engl J Med. 1999 Aug 19; 341(8):549-55.
    View in: PubMed
  69. Varvogli L, Waisbren SE. Personality profiles of mothers of children with mitochondrial disorders. J Inherit Metab Dis. 1999 Jun; 22(5):615-22.
    View in: PubMed
  70. St James PS, Shapiro E, Waisbren SE. The Resource Mothers Program for Maternal Phenylketonuria. Am J Public Health. 1999 May; 89(5):762-4.
    View in: PubMed
  71. Waisbren SE. Developmental and neuropsychological outcome in children born to mothers with phenylketonuria. Mental Retardation and Developmental Disabilities Research Reviews. 1999; 5:125-131.
  72. Waisbren SE, Chang P, Levy HL, Shifrin H, Allred E, Azen C, de la Cruz F, Hanley W, Koch R, Matalon R, Rouse B. Neonatal neurological assessment of offspring in maternal phenylketonuria. J Inherit Metab Dis. 1998 Feb; 21(1):39-48.
    View in: PubMed
  73. Waisbren SE. Breaking the barriers to full participation even when you have PKU. Family Futures Magazine. 1998; 2:19-21.
  74. Waisbren SE, Rokni H, Bailey I, Rohr F, Brown T, Warner-Rogers J. Social factors and the meaning of food in adherence to medical diets: results of a maternal phenylketonuria summer camp. J Inherit Metab Dis. 1997 Mar; 20(1):21-7.
    View in: PubMed
  75. Kim SZ, Varvogli L, Waisbren SE, Levy HL. Hydroxyprolinemia: comparison of a patient and her unaffected twin sister. J Pediatr. 1997 Mar; 130(3):437-41.
    View in: PubMed
  76. The Resource Mothers' Book. 1997.
  77. Rohr, F, Waisbren SE. Maternal PKU Treatment Plan. 1997.
  78. Skitnevsky SF, Brown M, Waisbren SE. Make a World of Difference: A Manual for Organizing a Maternal PKU Camp. 1997.
  79. Waisbren SE. Social support programs for individuals with PKU and their families. Proceedings of the 11th European Society for Phenylketonuria Annual Meeting. 1997; 11:11-15.
  80. Levy HL, Waisbren SE, Lobbregt D, Allred E, Leviton A, Koch R, Hanley WB, Rouse B, Matalon R, de la Cruz F. Maternal non-phenylketonuric mild hyperphenylalaninemia. Eur J Pediatr. 1996 Jul; 155 Suppl 1:S20-5.
    View in: PubMed
  81. Waisbren SE, Hamilton BD, St James PJ, Shiloh S, Levy HL. Psychosocial factors in maternal phenylketonuria: women's adherence to medical recommendations. Am J Public Health. 1995 Dec; 85(12):1636-41.
    View in: PubMed
  82. North KN, Korson MS, Gopal YR, Rohr FJ, Brazelton TB, Waisbren SE, Warman ML. Neonatal-onset propionic acidemia: neurologic and developmental profiles, and implications for management. J Pediatr. 1995 Jun; 126(6):916-22.
    View in: PubMed
  83. Newborn Screening and Societal Impact: A Case Study of Maternal PKU. 1995.
  84. Levy HL, Waisbren SE, Lobbregt D, Allred E, Schuler A, Trefz FK, Schweitzer SM, Sardharwalla IB, Walter JH, Barwell BE, et al. Maternal mild hyperphenylalaninaemia: an international survey of offspring outcome. Lancet. 1994 Dec 10; 344(8937):1589-94.
    View in: PubMed
  85. Levy HL, Waisbren SE. PKU in adolescents: rationale and psychosocial factors in diet continuation. Acta Paediatr Suppl. 1994 Dec; 407:92-7.
    View in: PubMed
  86. Waisbren SE, Brown MJ, de Sonneville LM, Levy HL. Review of neuropsychological functioning in treated phenylketonuria: an information processing approach. Acta Paediatr Suppl. 1994 Dec; 407:98-103.
    View in: PubMed
  87. Waisbren SE, Zaff J. Personality disorder in young women with treated phenylketonuria. J Inherit Metab Dis. 1994; 17(5):584-92.
    View in: PubMed
  88. St James PJ, Younger MD, Hamilton BD, Waisbren SE. Unplanned pregnancies in young women with diabetes. An analysis of psychosocial factors. Diabetes Care. 1993 Dec; 16(12):1572-8.
    View in: PubMed
  89. Waisbren SE. Phenylketonuria. Handbook of Neurodevelopmental and Genetic Disorders in Children. 1993; 433-458.
  90. Waisbren SE, Shiloh S, St James P, Levy HL. Psychosocial factors in maternal phenylketonuria: prevention of unplanned pregnancies. Am J Public Health. 1991 Mar; 81(3):299-304.
    View in: PubMed
  91. Waisbren SE, Levy HL. Agoraphobia in phenylketonuria. J Inherit Metab Dis. 1991; 14(5):755-64.
    View in: PubMed
  92. Shiloh S, St James P, Waisbren S. The development of a patient knowledge test on maternal phenylketonuria. Patient Educ Couns. 1990 Oct; 16(2):139-46.
    View in: PubMed
  93. Waisbren SE, Levy HL. Effects of untreated maternal hyperphenylalaninemia on the fetus: further study of families identified by routine cord blood screening. J Pediatr. 1990 Jun; 116(6):926-9.
    View in: PubMed
  94. Shiloh S, Waisbren SE, Levy HL. A psychosocial model of a medical problem: Maternal phenylketonuria. J Prim Prev. 1989 Sep; 10(1):51-62.
    View in: PubMed
  95. Waisbren SE, Doherty LB, Bailey IV, Rohr FJ, Levy HL. The New England Maternal PKU Project: identification of at-risk women. Am J Public Health. 1988 Jul; 78(7):789-92.
    View in: PubMed
  96. Waisbren SE, Mahon BE, Schnell RR, Levy HL. Predictors of intelligence quotient and intelligence quotient change in persons treated for phenylketonuria early in life. Pediatrics. 1987 Mar; 79(3):351-5.
    View in: PubMed
  97. Rohr FJ, Doherty LB, Waisbren SE, Bailey IV, Ampola MG, Benacerraf B, Levy HL. New England Maternal PKU Project: prospective study of untreated and treated pregnancies and their outcomes. J Pediatr. 1987 Mar; 110(3):391-8.
    View in: PubMed
  98. Levy HL, Waisbren SE. The PKU Paradigm: The mixed results from early dietary treatment. Amino Acids in Health and Disease: New Perspectives. 1987; 539-551.
  99. Waisbren SE, Schnell R, Levy HL. Intelligence and personality characteristics in adults with untreated atypical phenylketonuria and mild hyperphenylalaninemia. J Pediatr. 1984 Dec; 105(6):955-8.
    View in: PubMed
  100. Levy HL, Waisbren SE. Effects of untreated maternal phenylketonuria and hyperphenylalaninemia on the fetus. N Engl J Med. 1983 Nov 24; 309(21):1269-74.
    View in: PubMed
  101. Waisbren SE, Norman TR, Schnell RR, Levy HL. Speech and language deficits in early-treated children with galactosemia. J Pediatr. 1983 Jan; 102(1):75-7.
    View in: PubMed
  102. Waisbren SE, Levy HL, Schnell RR. Diet termination in children with phenylketonuria. A review of psychological assessments used to determine outcome. J Inher Met Dis. 1980; 3:149-153.
  103. Waisbren SE, Schnell RR, Levy HL. Diet termination in children with phenylketonuria: a review of psychological assessments used to determine outcome. J Inherit Metab Dis. 1980; 3(4):149-53.
    View in: PubMed
  104. Waisbren SE. Parents' reactions after the birth of a developmentally disabled child. Am J Ment Defic. 1980 Jan; 84(4):345-51.
    View in: PubMed
  105. Waisbren, SE. Parents' reactions after the birth of a developmentally delayed child. 1978.
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact Human Resources at faculty_serviceshms.harvard.edu.
Waisbren's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts
_
Co-Authors
_
Similar People
_
Same Department
Physical Neighbors
_